CoChat

The combination of olaparib and camptothecin for effective radiosensitization

Open access

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. The purpose of this study was to investigate the characteristics of the sensitizing effect of olaparib for radiation and CPT in order to support clinical application of this agent. Methods: DLD-1 cells (a human colorectal cancer cell line) and H1299 cells (a non-small cell lung cancer cell line) with differences of p53 gene status were used. The survival of these cells was determined by clonogenic assay after treatment with drugs and X-ray irradiation. The γH2AX focus formation assay was performed to examine the influence of olaparib on induction and repair of double-stranded DNA breaks after exposure to radiation or CPT. Results: A radiosensitizing effect of olaparib was seen even at 0.01 μM. Its radiosensitizing effect after exposure for 2 h was similar to that after 24 h. H1299 cells with depletion or mutation of p53 were more radioresistant than H1299 cells with wild-type p53. However, similar enhancement of radiosensitization by olaparib was observed with all of the tested cell lines regardless of the p53 status. Olaparib also sensitized cells to CPT. This sensitizing effect was seen at low concentrations of olaparib such as 0.01 μM, and its sensitizing effect was the same at both 0.01 μM and 1 μM. The combination of olaparib and CPT had a stronger radiosensitizing effect. The results of the γH2AX focus assay corresponded with the clonogenic assay findings. Conclusion: Olaparib enhanced sensitivity to radiation and CPT at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1748-717x-7-62

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 a. The relationship between concentrations of olaparib and radiosensitizing effects. DLD-1 cells were treated with various concentrations of olaparib for 1 h before radiation and 24 h after radiation. b. The relationship between exposure time (1 h or 24 h) of olaparib and radiosensitizing effects. DLD-1 cells were treated with 1 μM of olaparib for 1 h before radiation and 1 h or 23 h after radiation. c. Clonogenic cell survival assay of H1299 cells with various status of p53 gene. m143, m175, and m248 were made with transfection of mutated p53 gene into codon 143, 175, 248 of H1299 cells, respectively. “Control”: treated with radiation alone; “Olaparib (+)”:treated with radiation and olaparib. Cells were treated with 1 μM of olaparib for 1 h before radiation and 2 h after radiation.
Figure 1 a. The relationship between concentrations of olaparib and radiosensitizing effects. DLD-1 cells were treated with various concentrations of olaparib for 1 h before radiation and 24 h after radiation. b. The relationship between exposure time (1 h or 24 h) of olaparib and radiosensitizing effects. DLD-1 cells were treated with 1 μM of olaparib for 1 h before radiation and 1 h or 23 h after radiation. c. Clonogenic cell survival assay of H1299 cells with various status of p53 gene. m143, m175, and m248 were made with transfection of mutated p53 gene into codon 143, 175, 248 of H1299 cells, respectively. “Control”: treated with radiation alone; “Olaparib (+)”:treated with radiation and olaparib. Cells were treated with 1 μM of olaparib for 1 h before radiation and 2 h after radiation.CC BY · PubMed Central
Figure 2 a. The effect of olaparib on CPT toxicity. DLD-1 cells were treated with 1 μM of olaparib and various cocentrations of CPT for 6 h. Values shown are the mean ± standard error of the mean. b. The relationship between concentrations of olaparib and sensitizing effects to CPT in DLD-1 cells. Cells were treated with 0.01 μM of CPT and various concentrations of olaparib for 6 h. Values shown are the mean ± standard error of the mean.
Figure 2 a. The effect of olaparib on CPT toxicity. DLD-1 cells were treated with 1 μM of olaparib and various cocentrations of CPT for 6 h. Values shown are the mean ± standard error of the mean. b. The relationship between concentrations of olaparib and sensitizing effects to CPT in DLD-1 cells. Cells were treated with 0.01 μM of CPT and various concentrations of olaparib for 6 h. Values shown are the mean ± standard error of the mean.CC BY · PubMed Central
Figure 3 a. Cell survivals with radiation combined with olaparib and/or CPT. DLD-1 cells were treated with 0.1 or 1 μM of olaparib and/or 0.01 μM of CPT for 4 h before irradiation and for 2 h after radiation. b. Radiosensitization with olaparib and/or CPT. Figure 3b was made by modifying Figure 3a. The survival fraction of CPT at 0 Gy in Figure 3a was corrected to 1.
Figure 3 a. Cell survivals with radiation combined with olaparib and/or CPT. DLD-1 cells were treated with 0.1 or 1 μM of olaparib and/or 0.01 μM of CPT for 4 h before irradiation and for 2 h after radiation. b. Radiosensitization with olaparib and/or CPT. Figure 3b was made by modifying Figure 3a. The survival fraction of CPT at 0 Gy in Figure 3a was corrected to 1.CC BY · PubMed Central
Figure 4 γH2AX foci at 24 hours after irradiation and cell cycle distribution. DLD-1 cells were treated with 4 Gy of radiation and/or 1 μM of olaparib for 8 h and/or 10nM of CPT for 6 h. (a) Foci of γH2AX and Rad51 in DLD-1 cells treated with various combinations of olaparib, CPT, or irradiation (IR). DAPI(4',6-diamidino-2-phenylindole) was used to stain nucleus. Ola(+): with olaparib. IR(−): without irradiation. (b) Results of cells that were positive for Rad51 foci. (c) Results of cells that were negative for Rad51 foci. (d) Cell cycle distributions.
Figure 4 γH2AX foci at 24 hours after irradiation and cell cycle distribution. DLD-1 cells were treated with 4 Gy of radiation and/or 1 μM of olaparib for 8 h and/or 10nM of CPT for 6 h. (a) Foci of γH2AX and Rad51 in DLD-1 cells treated with various combinations of olaparib, CPT, or irradiation (IR). DAPI(4',6-diamidino-2-phenylindole) was used to stain nucleus. Ola(+): with olaparib. IR(−): without irradiation. (b) Results of cells that were positive for Rad51 foci. (c) Results of cells that were negative for Rad51 foci. (d) Cell cycle distributions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 2

  1. Hall EJ Hall EJ, Giaccia AM DNA strand breaks and chromosomal aberrations Radiobiology for the radiologist, ed 2006 6 Lippincott Williams & Wilkins, Philadelphia 16 29
  2. Hall EJ Hall EJ, Giaccia AM Repair of radiation damage and the dose-rate effect Radiobiology for the radiologist, ed 2006 6 Lippincott Williams & Wilkins, Philadelphia 60 84

Cited by

See all 35

Metadata

Authors
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M.
Affiliations
  • Sapporo Medical University (JP)
  • Tokyo Institute of Technology (JP)
  • University of Fukui (JP)
  • Gunma University (JP)
Corresponding author
Sakata, Koh-ichi
Venue
Radiation Oncology
Published
2012-04-23
Volume
7
Issue
1
Pages
62-62
ISSN
1748-717X (ISSN-L)
OpenAlex
W2131874020
Cited by
33
References
21
Citations by year
2026: 3 · 2025: 2 · 2023: 3 · 2022: 3 · 2020: 2 · 2019: 2 · 2017: 2 · 2016: 6 · 2015: 3 · 2014: 5 · 2013: 2
FWCI
1.58
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Radiation Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology
  • Japan Society for the Promotion of Science (22390231, 21689033, 24390286, 24591845)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
Keywords
camptothecin, radiosensitization, PARP-1 inhibitors, topoisomerase I inhibitor, p53 status, DNA double-strand break repair, γH2AX foci, clonogenic survival, colorectal cancer, non-small cell lung cancer, combination therapy, radiotherapy, DNA damage response, single-strand breaks
MeSH terms
Camptothecin, Cell Survival, DNA Repair, Dose-Response Relationship, Drug, Flow Cytometry, Humans, Phthalazines, Piperazines, Radiation-Sensitizing Agents, Cell Line, Tumor, DNA Breaks, Double-Stranded

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The combination of olaparib and camptothecin for effective radiosensitization. https://app.cochat.ai/papers/10.1186/1748-717x-7-62
The paper
Miura, K., Sakata, K.-I., Someya, M., Matsumoto, Y., Matsumoto, H., Takahashi, A., & Hareyama, M. (2012). The combination of olaparib and camptothecin for effective radiosensitization. Radiation Oncology. https://doi.org/10.1186/1748-717x-7-62

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.